PTB蛋白:一种调控肿瘤代谢的RNA可变剪接调节因子

多聚嘧啶区结合蛋白(polypyrimidine tract binding protein,PTB或hnRNP I)是一种在细胞内部参与mRNA代谢过程的蛋白质。PTB蛋白可结合于核酸分子上富含嘧啶碱基的序列,对mRNA前体的剪接进行调控。如在部分肿瘤细胞中,PTB的表达量升高可对肿瘤代谢过程中关键的丙酮酸激酶M(pyruvate kinase M,PKM)基因的表达进行调控,通过抑制PKM基因的可变剪接的方式上调PKM2(pyruvate kinase M2,PKM2)的表达,进而强化肿瘤细胞的有氧糖酵解过程并促进肿瘤的发展。本文结合PTB蛋白的结构及其在PKM可变剪接过程中的调节机制,简要综述了PTB蛋白对肿瘤代谢的调控作用。     

《分子细胞》：多聚嘧啶串结合蛋白研究进展

来自武汉大学生命科学学院,加州大学圣地亚哥分校的研究人员采用CLIP—seq技术。在基因组水平认识了可变剪接调控蛋白PTB（多聚嘧啶串结合蛋白）结合靶标pre—mRNA的特征,揭示出该蛋白通过结合在pre-mRNA的不同位置而对可变外显子的剪接实行正负双向调控的机制,从而打破了已写入教科书的、认为PTB是可变剪接抑制蛋白的传统观念。这一研究成果公布在《分子细胞》（Molecular Cell）封面上。     

东方蜜蜂微孢子虫基因的可变剪接及可变腺苷酸化解析

本研究旨在基于已获得的第三代纳米孔全长转录组数据对东方蜜蜂微孢子虫Nosema ceranae基因的可变剪接(alternative splicing,AS)和可变多聚腺苷酸化(alternative polyadenylation,APA)进行分析.通过Astalavista软件鉴定东方蜜蜂微孢子虫基因的AS事件类型...     

U2AF65蛋白表达水平影响基因UBQLN1的可变剪接

目的:研究U2AF65蛋白的表达水平对基因UBQLN1可变剪接的影响。方法:应用pSR-GFP/Neo载体构建2个U2AF65-siRNA干扰载体,转染293T细胞,通过Western印迹、QRT-PCR检测干扰效果,RT-PCR验证基因UBQLN1的可变剪接。结果:利用设计的U2AF65-siRNA能够干扰细胞中U2AF65的表达;RT-PCR结果显示U2AF65表达水平的下降促使UBQLN1第8外显子的跳跃增加。结论:U2AF65可以通过表达水平的变化参与调控基因UBQLN1的可变剪接。     

多聚嘧啶序列结合蛋白（PTB）与HBV转录后调节元件（HPRE）结合抑制HBV表面抗原的基因表达

采用RT-PCR验证PTB与HPRE在体外的特异性结合。用HepG2.2.15细胞系、HBs-HPRE瞬时转染Hela细胞探讨PTB对HBV基因表达的影响。结果显示PTB能与HPRE特异性地结合。功能性研究证明PTB可以抑制HepG2.2.15细胞的HBsAg表达量,并呈浓度依赖性。由HPRE引起的HBsAg表达的增加也能被PTB所抑制。实验数据证明PTB通过与HPRE相互作用抑制HBsAg的基因表达。     

脑胶质瘤组织中胞质多聚腺苷酸化成分结合蛋白1、细胞周期蛋白B2的表达及临床意义

目的:检测脑胶质瘤组织中胞质多聚腺苷酸化成分结合蛋白1(CPEB1)、细胞周期蛋白B2(CCNB2)的表达,分析CPEB1、CCNB2表达与脑胶质瘤患者临床病理特征以及预后的关系。方法:选取2016年1月至2018年1月东莞松山湖中心医院神经外科收治的经手术切除的55例脑胶质瘤患者瘤组织标本(脑胶质瘤组)和50例颅脑损伤患者额叶或颞叶组织标本(对照组)。检测CPEB1、CCNB2表达,分析CPEB1、CCNB2表达与脑胶质瘤患者临床病理特征的关系。结合随访资料,采用Kaplan-Meier生存分析CPEB1、CCNB2阳性/阴性表达脑胶质瘤患者的预后差异及采用Cox比例风险回归分析其预后的影响因素。结果:脑胶质瘤组CPEB1、CCNB2阳性表达率均高于对照组(P<0.05)。肿瘤直径>2 cm、WHO分级Ⅲ级及远处转移的患者CCNB2阳性表达率高于肿瘤直径≤2 cm、WHO分级Ⅰ~Ⅱ级及无远处转移的患者(P<0.05);WHO分级Ⅲ级、远处转移患者的CPEB1阳性表达率高于WHO分级Ⅰ~Ⅱ级、无远处转移的患者(P<0.05)。CPEB1、CCNB2阳性表达患者3年生存率低于CPEB1、CCNB2阴性表达患者(P<0.05)。WHO分级Ⅲ级、CPEB1及CCNB2阳性表达是脑胶质瘤患者术后3年死亡的危险因素(P<0.05)。结论:脑胶质瘤组织中CPEB1、CCNB2的阳性表达率均升高,其与脑胶质瘤恶性生物学行为以及不良预后有关。     

沉默单核细胞趋化蛋白-1基因降低人食管癌EC109细胞的迁移及侵袭能力

单核细胞趋化蛋白-1(monocyte chemoattractant protein-1,MCP-1)是白色脂肪细胞分泌的炎症趋化刺激因子,属于趋化因子CC亚族,可促进肿瘤血管形成和细胞外基质降解,从而促进肿瘤细胞的浸润与转移。沉默MCP-1基因可显著抑制恶性肿瘤生长及转移,但其作用的分子机制尚不完全清楚。本研究应用小干扰RNA技术沉默人食管癌EC109细胞中MCP-1表达。细胞划痕试验显示,与对照组相比,沉默MCP-1基因可明显抑制食管癌EC109细胞迁移能力。Transwell 侵袭实验显示,沉默MCP-1基因后,EC109细胞侵袭能力降低。Western 印迹试验和RT-PCR试验揭示,沉默MCP-1基因后,细胞中MMP-7、MMP-9、TGF-β1及VEGF表达水平显著下降。研究结果提示,沉默MCP-1基因可通过抑制MMP-7、MMP-9、TGF-β1及VEGF表达,降低癌细胞迁移及侵袭能力。     

兔乳腺组织中与牛α_(s1)酪蛋白基因5′调节区特异结合的蛋白

α_((?)1)酪蛋白基因为编码ca~(++)敏感性酪蛋白的基因家族成员之一,在催乳素的作用下由乳腺组织特异地合成和分泌,并受糖皮质激素、孕酮等多种激素的诱导和调节。在酪蛋白基因的5′端存在数个可能起顺式调节作用的元件,     

Capture RIC-seq reveals positional rules of PTBP1-associated RNA loops in splicing regulation

1. Download : Download high-res image (176KB)
2. Download : Download full-size image

     

PTBP1 promotes the growth of breast cancer cells through the PTEN/Akt pathway and autophagy

Invasion and migration is the hallmark of malignant tumors as well as the major cause for breast cancer death. The polypyrimidine tract binding, PTB, protein serves as an important model for understanding how RNA binding proteins affect proliferation and invasion and how changes in the expression of these proteins can control complex programs of tumorigenesis. We have investigated some roles of polypyrimidine tract binding protein 1 (PTBP1) in human breast cancer. We found that PTBP1 was upregulated in breast cancer tissues compared with normal tissues and the same result was confirmed in breast cancer cell lines. Knockdown of PTBP1 substantially inhibited tumor cell growth, migration, and invasion. These results suggest that PTBP1 is associated with breast tumorigenesis and appears to be required for tumor cell growth and maintenance of metastasis. We further analyzed the relationship between PTBP1 and clinicopathological parameters and found that PTBP1 was correlated with her‐2 expression, lymph node metastasis, and pathological stage. This will be a novel target for her‐2(⁺) breast cancer. PTBP1 exerts these effects, in part, by regulating the phosphatase and tensin homolog‐phosphatidylinositol‐4,5‐bisphosphate 3‐kinase/protein kinase B (PTEN‐PI3K/Akt) pathway and autophagy, and consequently alters cell growth and contributes to the invasion and metastasis.     

RNA结合蛋白质HuR通过增加YAP1 mRNA稳定性促进白血病细胞增殖

RNA结合蛋白质人类抗原R(Hu R)与多种实体肿瘤的发生发展密切相关,但其在人急性髓系白血病(acutemyeloidleukemia,AML)中的功能和分子机制仍未阐明。本研究收集了30例临床初诊的AML病人和30例正常对照的外周血,分离单个核细胞,进行RT-qPCR法检测。结果显示,与正常对照相比,HuR在AML病人中呈显著表达上调趋势(3.17±1.12,P<0.05)。在AML细胞系HL-60中的功能检测发现,敲低内源性HuR后,对HL-60细胞培养12 h(0.17±0.07),24 h(0.38±0.05),36 h(0.51±0.03),48 h(0.69±0.05),60 h(0.92±0.08)和72 h(1.04±0.10)的增殖产生抑制作用(P<0.05)。同时,阻滞在G1期(47.3%±5.4)的HL-60细胞比例显著升高(P<0.05),而S期(37.5%±6.9)细胞比例显著降低(P<0.05)。相反,HuR的表达抑制对HL-60细胞向单核系分化产生促进作用。RNA免疫共沉淀法检测发现,HuR可与Hippo通路的Yes相关蛋白1关键效应基因(YAP1)的mRNA结合。后续的RNA稳定性检测发现,HuR的结合可以增强YAP1 mRNA的稳定性,进而促进YAP1的表达,并进一步影响YAP1下游基因的转录。综上所述,RNA结合蛋白质HuR可通过促进Hippo通路YAP1的表达参与AML发生发展的调节。     

PNRC1剪接变异体的鉴定及其在辅激活核受体介导基因转录功能上的比较

为分析富含脯氨酸核受体辅调节蛋白1(PNRC1)选择性剪接, 及比较PNRC1剪接变异体在辅激活核受体介导基因转录功能上的差异,在生物信息学方法分析PNRC1剪接变异体的基础上,设计一定的特异性引物,采用RT-PCR结合克隆测序的方法对这些剪接变异体进行验证. 利用酵母双杂交和荧光素酶报告系统实验,分析它们与核受体的相互作用及比较它们在辅激活核受体介导基因转录功能上的差异.结果显示,生物信息学预测的几个剪接变异体真实存在于人的组织和细胞系中,这些剪接变异体在与雌激素受体α(ERα)、类固醇衍生因子1(SF1)等核受体的相互作用的强度及辅激活核受体介导基因转录功能上存在较大的差异. 研究提示,PNRC1这些剪接变异体在体内可能发挥不同的功能.     

Neuronal regulation of pre-mRNA splicing by polypyrimidine tract binding proteins,PTBP1 and PTBP2

Alternative splicing patterns are regulated by RNA binding proteins that assemble onto each pre-mRNA to form a complex RNP structure. The polypyrimidine tract binding protein, PTB, has served as an informative model for understanding how RNA binding proteins affect spliceosome assembly and how changes in the expression of these proteins can control complex programs of splicing in tissues. In this review, we describe the mechanisms of splicing regulation by PTB and its function, along with its paralog PTBP2, in neuronal development.     

Long Non-coding RNA HOXA10-AS Promotes Invasion and Migration of Hepatocellular Carcinoma Cells

Some studies have showed that long non-coding RNA (lncRNA) HOXA10-AS acts as an oncogene and regulates the invasion and metastasis of tumor cells. However, its mechanism in the invasion and migration of hepatocellular carcinoma (HCC) cells is unclear. The purpose of this study was to analyze the expression of HOXA10-AS in HCC tissues and its clinical significance, detect the influence of HOXA10-AS on the invasion and migration of HCC cells, and explore the mechanism of HOXA10-AS in promoting the invasion and migration of HCC cells. The results of quantitative real-time PCR (qRT-PCR) showed that the expression of HOXA10-AS was significantly upregulated in HCC tissues compared with the adjacent non-HCC tissues. Age and gender did not show significant correlation with HOXA10-AS expression, while tumor size, lymphatic metastasis and distant metastasis showed significant correlation with HOXA10-AS expression. Meanwhile, the expression of HOXA10-AS in HCC cells was higher than that in normal liver cells. After interfering with HOXA10-AS in HCC cell lines HepG2 and QGY7701, Transwell invasion and scratch experiments showed that the invasion and migration ability of HOXA10-AS cells in the HOXA10-AS group was significantly lower than that in the control group. Western blotting results showed that the expression levels of vimentin and N-cadherin were significantly lower than those of the control group, while the E-cadherin expression was significantly increased. The TGFβ1/Smads signaling pathway was inhibited after HOXA10-AS interference. In summary, HOXA10-AS promotes the invasion and migration of HCC cells by the TGFβ1/Smads signaling pathway.     

Splicing factor poly(rC)-binding protein 1 is a novel and distinctive tumor suppressor

A lot of evidence has been found on the link between tumorigenesis and the aberrant expression of splicing factors. A number of splicing factors have been reported to be either oncogenic or overexpressed in cancer cells. However, splicing factors can also play negative roles in tumorigenesis. In the current review, we focus on splicing factor poly(rC)-binding protein 1 (PCBP1), a novel tumor suppressor that is characterized by downregulation in many cancer types and shows inhibition of tumor formation and metastasis. Notably, the messenger RNA levels of PCBP1 are not significantly decreased in most cancer types. In fact, PCBP1 protein is often degraded or shows a loss-of-function through phosphorylation in cancer cells. PCBP1 is highly homologous to its family member, PCBP2. Interestingly, PCBP2 appears to be an oncogenic splicing factor. A growing body of evidence has shown that PCBP1 regulates alternative splicing, translation, and RNA stability of many cancer-related genes. Taking together, PCBP1 has distinctive tumor suppressive functions, and increasing PCBP1 expression may represent a new approach for cancer treatment.     

棉花腺苷酸核糖基化作用因子1(arf1)的结构特征、替换剪接和遗传表达分析

用已建立的新型染色体步移技术同尾酶反向PCR和快速分离目的基因cDNA 5′未知序列方法从陆地棉品种Y18中分离到腺苷酸核糖基化作用因子1(arf1)的全长cDNA、DNA和启动子序列。结果表明,该基因全长4360bp,具有6个内含子和7个外显子,在第一个内含子处存在替换剪接现象,使该基因在棉花中分别形成1026、1103和1544bp的3种mRNA。该基因编码181个氨基酸,转录起始位点上游具有转录起始子、TATA盒、CAAT盒、GC盒、多个正向重复序列和反向重复序列,在转录起始位点下游具有富含AT序列和回文结构等启动子特征序列。Southern杂交结果表明：该基因在棉花基因组中有两个拷贝。Northern杂交结果表明：该基因在棉花的蕾、花、纤维和铃壳等生殖器官中呈优势表达。     

AQP1促进肺动脉平滑肌细胞的增殖与迁移（应作者要求撤稿）

该文应作者要求已撤稿。肺动脉平滑肌细胞（PASMCs）的迁移和增殖是肺动脉重塑进而造成肺动脉高压的主要病理基础。水通道蛋白1（AQP1）具有促进上皮细胞、内皮细胞迁移的作用,但机制不清。由于AQP1也表达于血管平滑肌细胞,推测AQP1可能参与缺氧诱导的PASMCs增殖及迁移。通过PCR和免疫印迹分析,检测AQP的表达以及缺氧对AQP表达水平的影响,并通过细胞迁移以及增殖实验观察AQP1在缺氧诱导的PASMCs迁移与增殖中的作用。AQP1在PASMCs和主动脉平滑肌细胞（AoSMCs）均表达,但缺氧只增加PASMCs中AQP1的表达,以及促进PASMCs的迁移与增殖。敲除AQP1可抑制PASMCs的增殖以及缺氧诱导的细胞增殖和迁移。过表达AQP1促进PASMCs的增殖和迁移。缺氧促进β联蛋白在PASMCs内的表达。敲除β联蛋白后,抑制AdAQP1所介导的PASMCs迁移与增殖。这些结果表明,缺氧可促进AQP1在肺动脉内的表达,AQP1可通过β联蛋白对PASMCs的增殖和迁移进行调节。